Yu H, Zhu SC, Xu SG. Value of Bifico in rescue therapy for
Helicobacter pylori eradication.
Shijie Huaren Xiaohua Zazhi 2016;
24:2108-2112. [DOI:
10.11569/wcjd.v24.i13.2108]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the efficacy and safety of Bifico in rescue therapy for Helicobacter pylori (H. pylori) eradication.
METHODS: Two hundred and twenty H. pylori-infected patients after failed initial treatment were randomized into either a study group (n = 110) or a control group (n = 110). The control group was treated with rabeprazole, amoxicillin and furazolidone. The study group was additionally given Bifico on the basis of the drugs used in the control group. The rate of H. pylori eradication, relief of gastrointestinal symptoms and incidence of adverse reactions at 4 wk after treatment were compared in the two groups.
RESULTS: The rate of H. pylori eradication by per-protocol (PP) analysis in the study group (87.0%) was significantly higher than that in the control group (72.2%). The rate of H. pylori eradication by intention-to-treat (ITT) analysis in the study group (85.5%) was also significantly higher than that in the control group (70.9%). The rate of relief of epigastric distention in the study group (99.1%) was significantly higher than that in the control group (78.7%). The rate of relief of belching in the study group (96.3%) was also significantly higher than that in the control group (81.5%). The incidence of adverse reactions in the study group (1.9%) was significantly lower than that in the control group (9.3%).
CONCLUSION: Bifico can improve the efficacy of rescue therapy for H. pylori eradication, with higher H. pylori eradication rate and less adverse reactions.
Collapse